Category: News
-
Vyome’s stock rises on positive Phase II data for wound care drug
Vyome’s VT-1953 gel significantly reduced odor and pain in malignant fungating wounds, prompting plans for a pivotal Phase III study.
-
ASH25: Tessera’s gene writing hits curative thresholds in sickle cell
New preclinical data show Gene Writing tech exceeding key efficacy benchmarks for sickle cell disease and in vivo CAR-T generation.
-
Dicot Pharma unlocks sustained ED effect with LIB-01
Swedish company reveals how LIB-01, an erectile dysfunction therapy, works via the melanocortin system, offering sustained effects and possible hope for non-responders.
-
AVITA’s spray on skin cells slashes pain and hospital stays
Dr. Victoria Miles discusses how RECELL, which creates an autologous skin cell suspension, is reshaping burn care, access, and outcomes.
-
Iolyx and Théa partner on $280 million autoimmune eye drug deal
Concurrently with the collaboration deal for ILYX-002 for autoimmune-associated dry eye disease, Iolyx announced a $15 million Series B financing.
-
The $1 trillion blind spot: Bridging the gap in women’s health
Dr. Christian Tidona, founder and CEO of BioMed X, on why women’s health is critically underfunded and how a new initiative aims to change that.
-
Pharvaris stock rises following positive Phase III topline data
The company’s oral drug deucrictibant significantly sped up symptom relief in the Phase III trial, positioning it for 2026 regulatory filings.
-
Brainomix’s AI stroke tool doubles life-saving surgery rates in NHS study
The study indicated that Brainomix 360 Stroke led to a 100% increase in endovascular thrombectomy rates and sped up patient transfers across 107 UK hospitals.
-
Regeneron and Tessera ink $275 mil pact for gene editing therapy
The companies will co-develop TSRA-196, a potential one-time genetic treatment for alpha-1 antitrypsin deficiency.
-
Santersus secures funding to advance blood purification tech
Swiss biotech raises Series A financing to drive pivotal trials for its blood purification technology for sepsis and lupus therapy.
-
Saliva pregnancy test hits Australian shelves
Salignostics partners with Coles Supply to launch its innovative SaliStick saliva-based pregnancy test across Australia.
-
Biocomposites gains wider antimicrobial approval in India
The company’s Stimulan Rapid Cure can now be mixed with more antibiotics and antifungals in India to combat surgical infections.
Latest posts
-
Navigating the Risks and Rewards of Biomarker-Based Surrogates and Accelerated Approval
The risks and rewards of biomarker-based surrogates are crucial for optimizing clinical trial outcomes and guiding effective treatments.
-
ASH25: Gallop’s LYT-200 shows unprecedented survival in AML
The company’s execs talk about the striking efficacy and safety signals seen in Phase I data, the science behind the molecule, and their vision for transforming AML therapy.
-
Promis reports first human evidence of aβ oligomer reduction by pmn310
PMN310 demonstrates dose-dependent reduction of amyloid-beta oligomers in human CSF, marking a key milestone in Alzheimer’s treatment development.
-
Urologic Health secures $11 million for non-invasive bladder monitoring
Urologic Health raises $11million seed funding to advance a catheter-free bladder monitoring platform toward FDA clearance and US market entry.
-
Novo Nordisk’s denecimig cuts bleeding in hemophilia A regardless of inhibitors
Phase III trial shows once‑monthly and once‑weekly denecimig (Mim8) significantly reduces annualized bleeding rate versus standard care, with up to 95% of patients bleed‑free.